Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) Shares Outstanding (Weighted Average) (2019 - 2025)

aTYR PHARMA's Shares Outstanding (Weighted Average) history spans 7 years, with the latest figure at $93.0 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 25.21% year-over-year to $93.0 million; the TTM value through Dec 2025 reached $93.0 million, up 25.21%, while the annual FY2025 figure was $93.0 million, 25.21% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $93.0 million in Q4 2025 per ATYR's latest filing, down from $97.2 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $97.2 million in Q3 2025 to a low of $14.1 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $51.6 million, with a median of $54.4 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): surged 108.3% in 2021, then increased 23.38% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $19.1 million in 2021, then soared by 48.94% to $28.4 million in 2022, then soared by 88.63% to $53.6 million in 2023, then surged by 38.53% to $74.3 million in 2024, then rose by 25.21% to $93.0 million in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Shares Outstanding (Weighted Average) are $93.0 million (Q4 2025), $97.2 million (Q3 2025), and $88.3 million (Q2 2025).